Skip to main content

FDA Updates

Braftovi Plus Mektovi a New Combination for Unresectable or Metastatic Melanoma with BRAF Mutation

Lenvima Now Approved for Unresectable Hepatocellular Carcinoma

A Dynamic FDA Has Led to More Rapid Cancer Drug Development

Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation

Welcome to the Third Annual Oncology Guide to New FDA Approvals

FDA Approvals in 2017 Represent a 21-Year High

FDA Approvals of Brand-Name Prescription Cancer Drugs in 2017

Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation

Calquence (Acalabrutinib) Approved for Relapsed or Refractory Mantle-Cell Lymphoma in Adults

Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma and for Chronic Graft-versus-Host Disease

20
21
22
23
24
25
26

Page 23 of 33
Results 221 - 230 of 330